Author

Zaray Miranda-Chacón

Austral University of ChileORCID 0000-0002-4518-8807Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Molecular Biology· 1 Neuroscience· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Alberto Anastacio AmarillaiD· 2 shared Alejandro Rojas‐FernándeziD· 2 shared Alexander A. KhromykhiD· 2 shared Constanza Salinas-RebolledoiD· 2 shared Daniel WattersoniD· 2 shared Naphak ModhiraniD· 2 shared Adriana C. Pliego ZamoraiD· 1 shared Alexei Cuevas· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersNeuroscience

Alberto Anastacio AmarillaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike-ACE2 receptor interaction

Eduardo A. Albornoz, Alberto Anastacio Amarilla, Naphak Modhiran, Sandra E. Parker, Xaria X. Li, Danushka K. Wijesundara, Adriana C. Pliego Zamora, Christopher L. D. McMillan, Benjamin Liang, Nias Y. G. Peng, Julian D. J. Sng, Fatema Tuj Saima, Devina Paramitha, Rhys H. Parry, Michael Selorm Avumegah, , Trent M. Woodruff

This study shows SARS-CoV-2 activates microglial NLRP3 inflammasome via spike-ACE2 interaction, potentially linking viral infection to neurological symptoms like Parkinson's.

bioRxiv · Jan 11, 2022 · PreprintNeuroscience

Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity Nanobody.

Guillermo Valenzuela, Ronald Jara, Daniel Watterson, Naphak Modhiran, Alberto Anastacio Amarilla, Johanna Himelreichs, Alexander A. Khromykh, Constanza Salinas-Rebolledo, Teresa Pinto, Yorka Cheuquemilla, Yago Margolles, Natalia López‐González del Rey, Zaray Miranda-Chacón, Alexei Cuevas, Anne Berking, , Alejandro Rojas‐Fernández

The paper describes the development of a high-affinity Nanobody against SARS-CoV-2 RBD that neutralizes wild-type and D614G variants with nanomolar potency.

Scientific Reports · Feb 8, 2021Peer-reviewedMolecular Biology